Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nektar Therapeutics (NKTR)

Nektar Therapeutics (NKTR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,434,463
  • Shares Outstanding, K 28,688
  • Annual Sales, $ 55,230 K
  • Annual Income, $ -164,080 K
  • EBIT $ -140 M
  • EBITDA $ -139 M
  • 60-Month Beta 1.16
  • Price/Sales 43.63
  • Price/Cash Flow N/A
  • Price/Book 19.05

Options Overview Details

View History
  • Implied Volatility 67.46% (-31.50%)
  • Historical Volatility 71.72%
  • IV Percentile 2%
  • IV Rank 0.50%
  • IV High 558.45% on 06/05/25
  • IV Low 65.00% on 08/28/25
  • Expected Move (DTE 25) 12.37 (12.05%)
  • Put/Call Vol Ratio 0.91
  • Today's Volume 16,813
  • Volume Avg (30-Day) 2,811
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 26,233
  • Open Int (30-Day) 30,691
  • Expected Range 90.24 to 114.98

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.73
  • Number of Estimates 6
  • High Estimate $-1.22
  • Low Estimate $-2.88
  • Prior Year $-3.30
  • Growth Rate Est. (year over year) +47.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
64.10 +58.85%
on 03/30/26
109.00 -6.58%
on 04/20/26
+29.60 (+40.99%)
since 03/20/26
3-Month
33.40 +204.87%
on 01/30/26
109.00 -6.58%
on 04/20/26
+65.60 (+181.05%)
since 01/20/26
52-Week
7.99 +1,174.41%
on 06/16/25
109.00 -6.58%
on 04/20/26
+92.28 (+966.68%)
since 04/17/25

Most Recent Stories

More News
52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin

29% and 31% of patients in the 18 µg/kg and 24 µg/kg extension arms, respectively, achieved new SALT Score ≤20 from week 36 to week 52 with continued twice-monthly treatment

NKTR : 100.65 (+18.61%)
Nektar Therapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - NKTR

LOS ANGELES , April 20, 2026 /PRNewswire/ --  The DJS Law Group reminds investors of a class action lawsuit against Nektar Therapeutics ("Nektar" or "the Company") (NASDAQ: NKTR ) for violations...

NKTR : 100.65 (+18.61%)
Pomerantz Law Firm Announces the Filing of a Class Action Against Nektar Therapeutics, Inc. and Certain Officers - NKTR

NEW YORK , April 16, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) and certain officers. ...

NKTR : 100.65 (+18.61%)
NKTR INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Nektar Therapeutics (NKTR) Investors of Securities Class Action Deadline on May 5, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Nektar To Contact Him Directly To Discuss Their Options

NKTR : 100.65 (+18.61%)
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Hiding Enrollment Protocol Failures: SueWallSt

Key Dates and Disclosure Events Shareholders Need to Know

NKTR : 100.65 (+18.61%)
NKTR Investors Have Opportunity to Lead Nektar Therapeutics Securities Fraud Lawsuit

NEW YORK , April 16, 2026 /PRNewswire/ -- 

NKTR : 100.65 (+18.61%)
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES , April 15, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against...

NKTR : 100.65 (+18.61%)
NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Failing Clinical Enrollment Standards: Levi & Korsinsky

Alert: Claims Focus on Alleged Misrepresentations About REZOLVE-AA Patient Enrollment Compliance

NKTR : 100.65 (+18.61%)
NKTR Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Nektar Therapeutics Securities Lawsuit -- The Gross Law Firm

NEW YORK , April 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of  Nektar Therapeutics (NASDAQ: NKTR).

NKTR : 100.65 (+18.61%)
Nektar Therapeutics (NKTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

BENSALEM, Pa. , April 13, 2026 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action...

NKTR : 100.65 (+18.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 80%. The market has entered extreme overbought territory.

See More Share

Business Summary

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration...

See More

Key Turning Points

3rd Resistance Point 89.36
2nd Resistance Point 88.15
1st Resistance Point 86.51
Last Price 100.65
1st Support Level 83.66
2nd Support Level 82.45
3rd Support Level 80.81

See More

52-Week High 109.00
Last Price 100.65
Fibonacci 61.8% 70.41
Fibonacci 50% 58.49
Fibonacci 38.2% 46.58
52-Week Low 7.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.